Metraipolis › archive › dc_ee80acfc3848

Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States-January-July, 2021 — Europe PMC PMID:35263352

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/35263352
DOI
10.1371/journal.pone.0264179
License (as archived)
CC0-1.0
Archived
2026-10-31T08:03:40.769Z
SHA-256 of the archived text
1c1e78c1f730132e3ddb7edc9e3e2c36afa446884eab131452c208eafbab98cd
Stable URL of this page
https://metraipolis.com/documento/dc_ee80acfc3848

How to cite

Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States-January-July, 2021 — Europe PMC PMID:35263352 — Europe PMC (en), https://europepmc.org/article/MED/35263352 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_ee80acfc3848 (Metraipolis archive dc_ee80acfc3848, sha256 1c1e78c1f730132e3ddb7edc9e3e2c36afa446884eab131452c208eafbab98cd)
BibTeX
@misc{dcee80acfc3848,
  title = {Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States-January-July, 2021 — Europe PMC PMID:35263352},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/35263352},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_ee80acfc3848; sha256 1c1e78c1f730132e3ddb7edc9e3e2c36afa446884eab131452c208eafbab98cd},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/35263352. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

As of March 2021, three COVID-19 vaccines had been authorized by the U.S. Food and Drug Administration (FDA) for use in the United States. Each has substantial efficacy in preventing COVID-19. However, as efficacy from trials was 156 million fully vaccinated people. With high SARS-CoV-2 transmission and increasing numbers of people vaccinated in the United States, vaccine breakthrough infections will continue to accumulate. Understanding expectations regarding number of vaccine breakthrough infections enables accurate public health messaging to help ensure that the occurrence of such cases does not negatively affect vaccine perceptions, confidence, and uptake.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-03-09).
Identificativi: PMID 35263352 · PMCID PMC8906607 · DOI 10.1371/journal.pone.0264179.
Pagina: https://europepmc.org/article/MED/35263352 — https://doi.org/10.1371/journal.pone.0264179. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-31T07:49:13.736Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.